Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data

About two and a half months after the FDA turned away their lead program, Mesoblast $MESO reported a Phase III miss Monday afternoon for their second clinical product. But the Australian biotech pointed toward data in a secondary endpoint it thinks the agency might find promising.